Early results from the TUSCANY trial highlight promising remission rates and safety for a new triplet therapy in treating ...

Updated data from the BEXMAB study reveals a significant increase in complete remission rates for patients with high-risk ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...

Cytopenia Linked to Lower Survival in Myelofibrosis Cytopenia at diagnosis was linked to poorer outcomes in patients with myelofibrosis, including a higher risk of progression to acute myeloid ...

KJ-C2320: Targeting CD38, for the treatment of acute myeloid leukemia (AML). An IIT has been initiated at the end of 2024. KJ-C2114: For the treatment of solid tumors.

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

We took advantage of the haemGx model to interrogate the origins of infant acute myeloid leukemia (infAML). We focused on MNX1-driven leukemia, representing the commonest genetic abnormality unique to ...

KJ-C2320: Targeting CD38, for the treatment of acute myeloid leukemia (AML). An IIT has been initiated at the end of 2024. KJ-C2114: For the treatment of solid tumors. KJ-C2526: Targeting NKG2DL, for ...